西米普利单抗在意大利晚期宫颈癌名义使用项目中的真实世界疗效与安全性:MITO 44 研究
该研究为意大利多中心真实世界回顾性队列研究,纳入2022年3月至2023年12月在12个MITO中心接受西米普利单抗治疗的135例晚期宫颈癌患者,评估无进展生存期等终点。中位无进展生存期4.0个月,中位总生存期12.0个月,PD-L1状态间无差异;常见药物相关不良事件为贫血(39.1%)和疲乏(27.8%),免疫相关不良事件发生率18.0%。研究证实西米普利单抗名义使用在真实世界中可行且可重复。
要点
- 中位无进展生存期4.0个月,中位总生存期12.0个月,PD-L1状态间无差异。
- 完全缓解或无疾病证据占8.6%,部分缓解占21.1%,疾病稳定占14.8%,进展占44.5%。
- 常见药物相关不良事件为贫血(39.1%)和疲乏(27.8%),免疫相关不良事件占18.0%。
核心结论
- 本研究证实西米普利单抗名义使用在意大利晚期宫颈癌真实世界实践中可行且可重复。
研究设计与样本
- 意大利多中心真实世界回顾性队列研究,纳入2022年3月至2023年12月在12个MITO中心接受西米普利单抗治疗的135例晚期宫颈癌患者。
主要发现
- 中位无进展生存期为4.0个月(范围3.0-6.0),中位总生存期为12.0个月(12.0-未达到),PD-L1状态间无差异。
- 完全缓解或无疾病证据占8.6%,部分缓解占21.1%,疾病稳定占14.8%,进展占44.5%。
- 最常见药物相关不良事件为贫血(39.1%)和疲乏(27.8%),免疫相关不良事件发生率为18.0%。
- 42%的患者有一种或多种合并症,高血压最常见(23.4%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with platinum based chemotherapy based on the results of EMPOWER-Cervical 1/GOG-3016/ENGOTcx9 trial. This real-world, retrospective cohort, multicenter study aimed at describing clinical outcomes of patients with advanced CC treated with cemiplimab in Italy. METHODS: The primary objective of the study was to assess the feasibility and the replicability of the initial results in a real world setting of cemiplimab nominal use. The primary endpoint of our analysis was progression free survival (PFS). Secondary endpoints included overall response rate (ORR), overall survival (OS) and safety data. RESULTS: From March 2022 to December 2023, 135 patients were treated in 12 Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) Centers. Forty-two percent of patients had one or more comorbidities, hypertension being the most common (23.4%). Median PFS was 4.0 months (range 3.0-6.0) and median OS was 12.0 months (12.0- NR) with no differences according to PD-L1 status. Complete response (CR) or no evidence of disease (NED) were observed in 8.6%; partial response (PR) in 21.1%, stable disease (SD) in 14.8% and progression was recorded in 44.5% of patients. Most common drug related adverse events (AEs) were anemia (39.1%) and fatigue (27.8%). Immune related AEs occurred in 18.0%. CONCLUSIONS: This study confirms the feasibility and the replicability of the cemiplimab nominal use in advanced CC, in a real-world practice in Italy.
引用
- Tuninetti V, Virano E, Salutari V, et al. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study. Eur J Cancer. 2024. PMID: 38598922. doi:10.1016/j.ejca.2024.114039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。